Reference Source

MSD (Japan) Co., Ltd. · 66-66 · JAPAN

For MSD (Japan) Co., Ltd. · 66-66 · JAPAN, import alert is 66-66; import alert name is "APIs That Appear To Be Misbranded Under 502(f)(1) Because They Do Not Meet The Requirements For The Labeling Exemptions In 21 CFR 201.122"; country is JAPAN; product is Levadopa; product code is 62 J - S 09 Levodopa (Anti-Parkinsonian), Active Pharm Ingred/Chems for Further Manuf; date published is 09/30/2009; address is Kowa Bldg.No.16 Annex, 9-20 , Tokyo, JAPAN, verified against its source on 2026-09-16.

Firm
MSD (Japan) Co., Ltd. verified
Import alert
66-66
Import alert name
"APIs That Appear To Be Misbranded Under 502(f)(1) Because They Do Not Meet The Requirements For The Labeling Exemptions In 21 CFR 201.122"
Country
JAPAN verified
Address
Kowa Bldg.No.16 Annex, 9-20 , Tokyo, JAPAN verified
Date published
09/30/2009 verified
Product code
62 J - S 09 Levodopa (Anti-Parkinsonian), Active Pharm Ingred/Chems for Further Manuf verified
Product
Levadopa verified
FDA notes
11/2/2000 verified
Sourceaccessdata.fda.gov
Verified
Review by
DatasetFDA import alert red lists: firms subject to detention without physical examination

What the source says

MSD (Japan) Co., Ltd. Date Published : 09/30/2009 Kowa Bldg.No.16 Annex, 9-20 , Tokyo, JAPAN 62 J - S 09 Levodopa (Anti-Parkinsonian), Active Pharm Ingred/Chems for Further Manuf Date Published: 04/01/2019 Desc: Levadopa Notes: 11/2/2000

accessdata.fda.gov, retrieved 2026-09-15

Source

Last verified against source: . Due for re-check by . This page as Markdown · OKF bundle · full dataset as JSON.

This one changes, and we watch it.FDA import alert red lists: firms subject to detention without physical examination is re-read on a schedule and every change is dated. Subscribe: Atom feed · JSON · what has changed so far.